Related Experiment Videos
[Immunotherapy of chronic inflammatory demyelinating polyneuropathy]
J D Lünemann1, K Prass, R Zschenderlein
1Klinik und Poliklinik für Neurologie, Campus Mitte, Charité-Universitätsmedizin Berlin. jan.luenemann@charite.de
Fortschritte Der Neurologie-Psychiatrie
|December 8, 2004
Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable nerve disorder. While first-line treatments are effective for many, some patients require alternative or combination therapies for durable clinical response.
Area of Science:
- Neurology
- Immunology
- Peripheral Nervous System Disorders
Context:
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated peripheral nerve disorder.
- It affects 1-2/100,000 individuals, presenting with heterogeneous clinical features, most commonly symmetrical muscle weakness.
- CIDP is considered treatable, with established first-line therapies.
Purpose:
- To review the current treatment landscape for CIDP.
- To evaluate the efficacy, tolerability, and cost-effectiveness of various therapeutic options.
- To identify treatment strategies for patients unresponsive to standard therapies.
Summary:
- First-line treatments for CIDP, including corticosteroids, plasmapheresis, and intravenous immunoglobulin, are effective in short-term trials for many patients.
- Approximately one-third of CIDP patients do not achieve a durable response with these initial treatments.
- Limited high-quality controlled trials exist for other immunosuppressive agents; cyclophosphamide and cyclosporine may benefit non-responders.
- Combination therapy is a potential strategy to improve efficacy in refractory CIDP cases.
Impact:
- Highlights the need for further research into effective treatments for non-responsive CIDP.
- Provides a framework for clinicians managing CIDP patients with varying treatment responses.
- Emphasizes the importance of considering efficacy, tolerability, and cost-effectiveness in therapeutic decision-making for CIDP.